Drug Topics May 21, 2024
Lauren Biscaldi, MS, Managing Editor

These aflibercept biosimilars are used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Earlier this week, the FDA approved aflibercept-jbvf (Yesafili) and aflibercept-yszy (Opuviz), the first interchangeable biosimilars for aflibercept (Eyela).1,2 These medications are used to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Both medications are vascular endothelial growth factor (VEGF) inhibitors, administered intravitreally as a 2 mg injectable solution. Anti-VEGF medications stop abnormal blood vessels from leaking, growing, and bleeding under the retina, which leads to pain and vision loss for patients.

More than 19 million Americans are living with age-related macular degeneration. The approval of these medications offers an additional treatment option to this...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article